Q-omics provides the consensus-scored SNORD62A profile across patient tissues and cancer cell-line models. SNORD62A expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SNORD62A is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, SNORD62A RNA expression shows 12,005 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, STAD, and THYM as cancer lineages where SNORD62A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD62A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD62A survival associations across molecular data types. SNORD62A RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD62A RNA expression–survival associations across cancer types. High SNORD62A expression shows unfavorable associations in MESO, SKCM, CHOL, LIHC and KIRC, but favorable associations in LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SNORD62A RNA expression.
This table summarizes SNORD62A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD62A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD62A shows higher tumor expression in STAD, HNSC, COAD, KIRP, KIRC and ESCA. The STAD box plot shows higher SNORD62A RNA expression in tumor versus normal tissue (log2 FC = +0.669, t-test p = .002).
This table shows molecular features associated with SNORD62A in patient tissues and cancer cell lines. In patient samples, SNORD62A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
